Protecting the Ignorant, the Unthinking and the Credulous: Are the FDA's Efforts to Accelerate the Drug Approval Process Compromising Public Safety?

Protecting the Ignorant, the Unthinking and the Credulous: Are the FDA's Efforts to Accelerate the Drug Approval Process Compromising Public Safety?

DSpace/Manakin Repository

Protecting the Ignorant, the Unthinking and the Credulous: Are the FDA's Efforts to Accelerate the Drug Approval Process Compromising Public Safety?

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Katz, Gail	en_US
dc.date.accessioned	2012-07-06T21:38:17Z
dc.date.issued	2000	en_US
dc.identifier.citation	Protecting the Ignorant, the Unthinking and the Credulous: Are the FDA's Efforts to Accelerate the Drug Approval Process Compromising Public Safety? (2000 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965591
dc.description.abstract	Recently, five approved prescription drugs were recalled in a one-year period after the Food and Drug Administration (FDA or the agency) deemed them to be too unsafe for patient use. Notorious among them was fenfluramine (Pondimin), the "fen" half of "fen-phen," a drug used to promote weight loss in patients. The list also includes Seldane, a popular antihistamine as well as Redux, Posicor, and the pain medication Duract. All had side effects not detected in clinical trials. This unusually high rate of withdrawals in such a short period of time sparked the most recent round of debate over the ever-controversial topic of the FDA drug approval process.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	FDA	en
dc.subject	recall	en
dc.subject	approval	en
dc.subject	access	en
dc.subject	safety	en
dc.subject	drugs	en
dc.title	Protecting the Ignorant, the Unthinking and the Credulous: Are the FDA's Efforts to Accelerate the Drug Approval Process Compromising Public Safety?	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-07-06T21:38:17Z